1. Introduction {#s1}
===============

At present, second-generation (2G)-drug-eluting stents (DES) have nearly replaced first-generation (1G)-DES during percutaneous coronary intervention (PCI) in our routine daily clinical practice. Although acute myocardial infarction (AMI) milieu tends to higher thrombotic condition compared to stable coronary artery disease, DES implantation during primary PCI or staged PCI commonly done from the beginning of DES era up to now. During the last few years, several studies demonstrated that 1G-DES such as sirolimus-eluting stent (SES, Cypher^®^, Cordis Corp., Miami Lakes, Florida)[@b1] or paclitaxel-eluting stent (PES, Taxus^®^, Boston Scientific, Natick, Massachusetts)[@b2] were associated with reductions in angiographic target vessel revascularization (TVR) and major adverse cardiac events (MACE) compared with bare-metal stents (BMS). Chen, *et al*.[@b3] reported everolimus-eluting stent (EES, Xience V^®^, Abbott Vascular, Santa Clara, CA) in the setting of AMI appears to be superior to PESs in reducing target lesion failure, and stent thrombosis (ST). Kang, *et al*.[@b4] also reported Zotarolimus-eluting stent (ZES, Resolute^®^, Medtronic Inc, Santa Rosa, California) showed similar rates of MACE, cardiac death and recurrent myocardial infarction (MI) compared with SES and PES at 12 months and 18 months of follow-up periods in patients with ST-segment elevation MI (STEMI) who undergoing primary PCI. Most 2G-DES were showed non-inferior clinical outcomes compared with 1G-DES.[@b5],[@b6] However, there is limited very long-term clinical outcome data comparing the safety and efficacy between 1G-DES and 2G-DES in patients with AMI who underwent successful PCI. Recently one all-comer, randomized, multicenter AMI trials[@b7] showed that cardiac death (EES: 2.5% *vs*. SES: 2.7%, *P* = 0.86) and ST (EES: 2.3% *vs*. SES: 3.2%, *P* = 0.60) rates were comparable in both groups during 3--year follow-up periods. The aim of this study was to compare the efficacy and safety of 2G-DES with 1G-DES in AMI patients during long-term clinical follow-up periods.

2. Methods {#s2}
==========

This study is a single-center, prospective, all-comers registry designed to reflect the "real world" practice since 2004. Data were collected by a trained study-coordinator with a standardized case report form. This study examined and approved by the institutional review committee and the subjects gave informed written consent. This study performed in accordance with the ethical standards laid down in the 1964 declaration of Helsinki. Informed consent was obtained from all individual participants included in the study prior to enrollment.

2.1. Study design and population {#s2a}
--------------------------------

A total 1161 AMI patients were underwent coronary angiography (CAG) from January 2004 to October 2012. Among them, these patients were excluded if they had: (1) BMS (*n* = 26), (2) other types of DES \[except for SES, PES, 1G-ZES (endeavor, endeavor sprint), 2G-ZES (endeavor resolute) and EES, *n* = 40\] implantation, (3) stent size required to treat lesion \> 3.5 mm (maximum diameter of SES, *n* = 61), (4) not participated or follow-up loss (*n* = 18). Finally, a total 1016 eligible AMI patients who treated with 1G-DES (SES, PES, or 1G-ZES, total *n* = 554) or 2G-DES (2G-ZES, or EES, total *n* = 462) were enrolled. After a propensity score matched (PSM) analysis, two propensity-matched groups (232 pairs, *n* = 464) were generated ([Figure 1](#jgc-15-08-523-g001){ref-type="fig"}).
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2.2. PCI procedure and medical treatment {#s2b}
----------------------------------------

A diagnostic CAG and PCI done through either trans-femoral or trans-radial approaches after an administration of unfractionated heparin (70--100 IU/kg). Patients\' activated clotting time maintained above 250 seconds during the procedure. All patients received a loading dose of 200 to 300 mg aspirin and 300 to 600 mg of clopidogrel as the dual antiplatelet therapy (DAPT) and maintained with 100 mg of aspirin and 75 mg of clopidogrel. The use of cilostazol (Pletaal^®^, Otsuka Pharmaceutical Co., Tokyo, Japan) or platelet glycoprotein IIb/IIIa receptor blockers was left to the discretion of the individual operators. After stent implantation, DAPT (100 mg daily aspirin and 75 mg daily clopidogrel) prescribed at least 12 months. During hospitalization, enrolled patients had taken cardiovascular beneficial medications, including beta-blockers (BB), angiotensin converting enzyme inhibitors (ACEI), or angiotensin receptor blockers (ARB), calcium channel blockers (CCB), and lipid lowering agents. After discharge, the patients were encouraged to stay on the same medications they received during hospitalization.

2.3. Study deﬁnitions and clinical follow-up {#s2c}
--------------------------------------------

The recording of cardiovascular risk factors and past medical histories based on patients\' self-report. The primary endpoint was the occurrence of MACE defined as total death, recurrent non-fatal MI, target lesion revascularization (TLR), TVR, Non-TVR. The secondary endpoint was ST. All deaths classified as cardiac or non-cardiac death. Re-AMI was deﬁned as the presence of clinical symptoms, electrocardiographic changes, or abnormal imaging findings of MI, combined with an increase in the creatine kinase myocardial band fraction above the upper normal limits or an increase in troponin-T/troponin-I to greater than the 99^th^ percentile of the upper normal limit. TLR was deﬁned as a revascularization of the target lesion due to restenosis or re-occlusion within the stent or 5 mm in and adjacent of the distal or proximal segment. TVR was defined as a revascularization of the target vessel or any segment of the coronary artery containing the target lesion. Non-TVR defined as a revascularization of any segment of the non-target coronary artery. Multi-vessel disease was defined as the presence of a lesion with \> 50% diameter stenosis in a non--infarct related coronary artery by visual estimation. ST defined as acute (0--24 h), subacute (24 h--30 d), late (30 d--1 year) and very late (\> 1 year) according to the onset time of stent thrombosis.[@b8] The participants were required to visit the outpatient department of cardiology at the end of the ﬁrst month and then every 3 to 6 months after the index PCI procedure and we could follow up on the clinical data of all enrolled patients through face-to-face interviews at regular outpatient clinic, medical chart reviews, and telephone contacts.

2.4. Statistical analysis {#s2d}
-------------------------

For continuous variables, differences between the two groups evaluated with the unpaired *t*-test or Mann-Whitney rank test. Data expressed as mean ± SD. For discrete variables, differences expressed as counts and percentages and analyzed with *χ*^2^ or Fisher\'s exact test between the groups as appropriate. To adjust for any potential confounders, PSM analysis performed using the logistic regression model. We tested all available variables which could be of potential relevance; gender (men), age, left ventricular ejection fraction (LVEF), STEMI, known cardiovascular diseases (CVD) risk factors, chronic kidney disease, routine angiographic follow-up (RAF), laboratory findings and post-PCI medications (aspirin, clopidogrel, cilostazol, BB, CCB, ACEI, ARB, diuretics, lipid lowering agents). Angiographic and procedural characteristics also considered as covariate. The propensity score (PS) was estimated with the use of C-statistic for the logistic regression model and the C-statistics for the two groups was 0.802. Subjects matched with a caliper width equal to 0.01. Various clinical outcomes estimated with the Kaplan-Meier method, and differences between the two groups compared with the log-rank test. Proportional hazard models used to assess the hazard ratio of the 1G-DESs compared with 2G-DESs adjusted PS. For all analyses, a 2-sided *P* \< 0.05 considered statistically significant. All data processed with SPSS (version 20.0, SPSS-PC, Inc. Chicago, Illinois).

3. Results {#s3}
==========

3.1. Baseline clinical and angiographic characteristics {#s3a}
-------------------------------------------------------

Baseline clinical and angiographic characteristics shown in [Table 1](#jgc-15-08-523-t01){ref-type="table"}. Before PSM adjustment, the mean age of the 1G-DES group was 61.9 ± 11.8 years and 2G-DES was 63.0 ± 12.9 years (*P* = 0.183). Gender distribution was also similar between the two groups (69.3% *vs*. 74.0%, *P* = 0.098). The LVEFs were significantly higher in the 2G-DES compared with 1G-DES (49.9 ± 11.2 % *vs*. 45.7 ± 10.5%, *P* \< 0.001). The histories of previous CVA, MI and PCI were significantly frequent in the 1G-DES. Routine follow-up angiography was more frequently done in the 1G-DES (67.9% *vs*. 41.3%, *P* \< 0.001). In the aspect of angiographic and procedural characteristics, American College of Cardiology/American Heart Association (ACC/AHA) type B2 and C lesion were more common in 2G-DES and the use of intra-aortic balloon pump (IABP) was more common in 1G-DES. Mean total stent length (25.6 ± 6.4 *vs*. 23.1 ± 6.4 mm, *P* \< 0.001) and total procedure time (minutes, 48.4 ± 35.5 *vs*. 36.8 ± 24.1, *P* \< 0.001) were much longer in 1G-DES compared with 2G-DES. However, all of these differences were disappeared after PSM analysis.

###### Baseline and angiographic characteristics.

  Variables                                        Entire patients   Propensity-matched patients                                             
  ----------------------------------------------- ----------------- ----------------------------- ---------- --------------- --------------- -------
  Men                                                384 (69.3%)             342 (74.0%)            0.098      164 (70.7%)     161 (69.4%)    0.706
  Age, yrs                                           61.9 ± 11.8             63.0 ± 12.9            0.183      62.9 ± 11.8     62.8 ± 13.6    0.868
  LVEF, %                                            45.7 ± 10.5             49.9 ± 11.2           \< 0.001    48.0 ± 10.3     47.3 ± 11.9    0.471
  ST segment elevation MI                            282 (50.9%)             252 (54.5%)            0.247      121 (52.2%)     128 (55.2%)    0.515
  Hypertension                                       335 (60.5%)             262 (56.7%)            0.225      137 (59.1%)     123 (53.0%)    0.190
  Diabetes mellitus                                  174 (31.4%)             174 (37.7%)            0.036      89 (38.4%)      88 (37.9%)     0.924
  Dyslipidemia                                       127 (22.9%)             70 (15.2%)             0.002      41 (17.7%)      39 (16.8%)     0.806
  Previous cerebrovascular accident                   39 (7.0%)               13 (2.8%)             0.002       16 (6.9%)       10 (4.3%)     0.226
  Previous MI                                         14 (2.5%)               1 (0.2%)              0.002       1 (0.4%)        1 (0.4%)      1.000
  Previous PCI                                        34 (6.1%)               4 (0.9%)             \< 0.001     5 (2.2%)        4 (1.7%)      0.736
  Peripheral vascular disease                         13 (2.3%)               6 (1.3%)              0.220       6 (2.6%)        2 (0.9%)      0.154
  Chronic kidney disease                              33 (6.0%)               25 (5.4%)             0.709       15 (6.5%)       16 (6.9%)     0.853
  Routine angiographic follow-up                     376 (67.9%)             191 (41.3%)           \< 0.001    127 (54.7%)     128 (55.2%)    0.926
  CK-MB, mg/dL, initial                             100.1 ± 149.3           109.2 ± 146.0           0.330     84.1 ± 139.3    104.9 ± 141.1   0.112
  CK-MB, mg/dL, peak                                115.9 ± 153.3           121.3 ± 143.9           0.236     104.9 ± 147.2   117.9 ± 138.9   0.330
  Troponin T, ng/dL, initial                         1.19 ± 2.70             1.41 ± 3.02            0.236      1.21 ± 2.67     1.39 ± 3.42    0.312
  Troponin T, ng/dL, peak                            1.64 ± 3.19             1.69 ± 3.21            0.836      1.47 ± 3.07     2.00 ± 3.67    0.104
  High sensitivity CRP, mg/dL                        20.5 ± 38.2             14.7 ± 28.3            0.008      16.1 ± 28.7     16.7 ± 31.2    0.803
  Total cholesterol, mg/L                           181.9 ± 42.8            184.0 ± 43.4            0.441     181.2 ± 41.8    181.7 ± 44.9    0.448
  Triglyceride, mg/L                                128.5 ± 70.9            130.5 ± 116.6           0.810     139.3 ± 79.2    122.3 ± 104.5   0.130
  HDL cholesterol, mg/L                              43.9 ± 11.5             43.3 ± 10.1            0.522      43.4 ± 11.5     42.5 ± 10.2    0.492
  LDL cholesterol, mg/L                             118.5 ± 38.5            119.6 ± 37.7            0.762     122.9 ± 41.9    117.7 ± 39.2    0.282
  Serum creatinine, mg/L                             1.05 ± 0.80             1.04 ± 1.00            0.825      1.03 ± 0.46     1.10 ± 1.20    0.385
  Serum glucose, mg/dL                              134.2 ± 58.4            139.0 ± 70.1            0.260     138.1 ± 63.7    141.7 ± 72.4    0.584
  Hemoglobin A1~C~, %                                 6.5 ± 1.4               6.6 ± 1.5             0.665       6.9 ± 1.4       6.5 ± 1.2     0.065
  Angiographic characteristics                                                                                                               
   Target vessel                                                                                                                             
    Left anterior descending                         309 (55.8%)             276 (59.7%)            0.203      131 (56.5%)     144 (62.1%)    0.219
    Left circumflex                                  157 (28.3%)             139 (30.1%)            0.542      79 (34.1%)      69 (29.7%)     0.319
    Right coronary artery                            214 (38.6%)             167 (36.1%)            0.416      86 (37.1%)      87 (37.5%)     0.924
    Left main                                         25 (4.5%)               6 (1.3%)              0.003       12 (5.2%)       5 (2.2%)      0.084
    Ramus                                             6 (1.1%)                4 (0.9%)              0.727       2 (0.9%)        3 (1.3%)      0.653
    Number of multivessel disease (≥ 2 vessels)      133 (24.0%)             108 (23.4%)            0.814      64 (27.6%)      62 (26.7%)     0.835
   ACC/AHA Lesion type                                                                                                                       
    Type B1                                           9 (1.6%)                9 (1.9%)              0.697       3 (1.3%)         4(1.7%)      0.703
    Type B2                                           53 (9.6%)              112 (24.2%)           \< 0.001    36 (15.5%)      33 (14.2%)     0.695
    Type C                                           492 (88.8%)             341 (73.8%)           \< 0.001    193 (83.2%)     195 (84.1%)    0.802
   Extent of coronary artery disease                                                                                                         
    1-vessel                                         419 (75.6%)             354 (76.6%)            0.712      168 (72.4%)     170 (73.3%)    0.835
    2-vessel                                         114 (20.6%)             87 (18.8%)             0.487      51 (22.0%)      49 (21.1%)     0.821
    3-vessel                                          21 (3.8%)               21 (4.5%)             0.547       13 (5.6%)       13 (5.6%)     1.000
  Ostial lesion (≤ 5 mm)                             118 (21.3%)             81 (17.5%)             0.132       13 (5.6%)       13 (5.6%)     1.000
  Bifurcation                                        205 (37.0%)             187 (40.5%)            0.258      85 (36.6%)      93 (40.1%)     0.445
  Heavy Calcification                                80 (14.4%)              68 (14.7%)             0.900      38 (16.4%)      39 (16.8%)     0.901
  IABP                                               106 (19.1%)              15 (3.2%)            \< 0.001     15 (6.5%)       14 (6.0%)     0.848
  Mean total stent length, mm                        25.6 ± 6.4              23.1 ± 6.4            \< 0.001    24.1 ± 6.7      24.8 ± 6.7     0.189
  Mean stent diameter, mm                            2.98 ± 0.38             2.92 ± 0.33            0.008      2.93 ± 0.39     2.94 ±0.32     0.543
  Number of stents/patient                           1.18 ± 0.56             1.18 ± 0.57            0.991      1.21 ± 0.62     1.22 ± 0.61    0.764
  Total procedure time, min                          48.4 ± 35.5             36.8 ± 24.1           \< 0.001    47.2 ± 39.6     45.2 ± 26.5    0.102

Values are mean ± SD or *n* (%). The *P* value for continuous data from analysis of variance; the *P* value for categorical data from chi-square test. ACC/AHA: American college of cardiology/American heart association; CK-MB: creatine kinase-muscle and brain; CRP: c-reactive protein; DESs: drug-eluting stents; HDL: high-density lipoprotein; Hemoglobin A1~C~: glycated hemoglobin; IABP: intra-aortic balloon pump; LDL: low-density lipoprotein; LVEF: left ventricular ejection fraction; MI: myocardial infarction; PCI: percutaneous coronary intervention; 1G: first-generation; 2G: second-generation.

3.2. Post-percutaneous coronary intervention medications {#s3b}
--------------------------------------------------------

[Table 2](#jgc-15-08-523-t02){ref-type="table"} shows post-PCI medications between the two groups. Before PSM analysis 1G-DES group was more likely to have received BB, CCB and ACEI after PCI than 2G-DES. But these differences were also disappeared after PSM analysis. The prescription rates of other kinds of medications including aspirin, clopidogrel, cilostazole (Pletaal^®^, Otsuka Pharmaceutical Co., Tokyo, Japan), ARB, diuretics and lipid lowering agents were similar between two groups before and after PSM analysis.

###### Post-percutaneous coronary intervention medications.

  Variables                   Entire patients   Propensity-matched patients                                         
  -------------------------- ----------------- ----------------------------- ---------- ------------- ------------- -------
  Aspirin                       504 (91.0%)             427 (92.4%)            0.406     214 (92.2%)   213 (91.8%)   0.864
  Clopidogrel                   505 (91.2%)             416 (90.0%)            0.544     217 (93.5%)   210 (90.5%)   0.230
  Cilostazol                    138 (24.9%)             102 (22.1%)            0.290     57 (24.6%)    45 (19.4%)    0.179
  Beta blockers                 291 (52.5%)             311 (67.3%)           \< 0.001   134 (57.8%)   144 (62.1%)   0.343
  Calcium channel blockers      203 (36.3%)             119 (25.8%)           \< 0.001   70 (30.2%)    65 (28.0%)    0.609
  ACEIs                         179 (32.3%)             211 (45.7%)           \< 0.001   88 (37.9%)    94 (40.5%)    0.588
  ARBs                          178 (32.1%)             126 (27.3%)            0.092     70 (30.2%)    73 (31.5%)    0.763
  Diuretics                     126 (22.7%)             99 (21.4%)             0.615     54 (23.3%)    57 (24.6%)    0.744
  Lipid lowering agents         469 (84.7%)             401 (86.8%)            0.333     199 (85.8%)   201 (86.6%)   0.788

Values are mean ± SD or *n* (%). The *P* value for categorical data from chi-square test. ACEIs: angiotensin converting enzyme inhibitors; ARBs: angiotensin receptor blockers; DESs: drug-eluting stents; 1G: first-generation; 2G: second-generation.

3.3. Clinical outcomes {#s3c}
----------------------

Clinical outcomes at 30 d, one year, 3 years and 5 years shown in [Table 3](#jgc-15-08-523-t03){ref-type="table"}. During one month, the incidence of MACE was not significantly different between the two groups. At 1 year after the index PCI, and the incidence of TLR and TVR was significantly higher in the 1G-DESs group compared with the 2G-DESs group before PSM (TLR: 8.8% *vs*. 3.2%, *P* \< 0.001; TVR: 10.1% *vs*. 3.7%, *P* \< 0.001) and after PSM analysis (TLR: 9.1% *vs*. 3.4%, *P* = 0.020; TVR: 9.5% *vs*. 3.9%, *P* = 0.024). At 5 years, the cumulative incidences of TLR \[hazard ratio (HR): 3.133; 95% confidence intervals (CI): 1.596--6.376; *P* = 0.002\] and TVR (HR: 3.144; 95% CI: 1.596--6.192; *P* = 0.001) were significantly higher in the 1G-DESs group compared with the 2G-DESs group after PSM analysis during 5-year follow-up period ([Table 4](#jgc-15-08-523-t04){ref-type="table"}). [Figure 2](#jgc-15-08-523-g002){ref-type="fig"} shows Kaplan-Meier curved analysis of MACE Free survival, TLR, TVR and ST at 5 years according to the generation of DESs (1G *vs*. 2G) and the types of DESs (SES *vs*. PES *vs*. 1G-ZES *vs*. 2G-ZES *vs*. EES). [Figure 3](#jgc-15-08-523-g003){ref-type="fig"} shows subgroup analysis for MACE and ST up to 5 years. Although, in cases of male, STEMI, non-small vessel disease (≥ 2.5 mm), the choice of 2G-DESs may be prefer rather than 1G-DESs to reduce MACE during PCI for AMI patients.

###### Clinical outcomes at 30 days, 1 year, 3 years and 5 years.

  Outcomes                                 Entire patients   Propensity-matched patients                                                    
  --------------------------------------- ----------------- ----------------------------- ------------ ---------- ------------ ------------ ----------
  30 d follow-up                                                                                                                            
   All death                                  40 (3.9%)               19 (3.4%)            21 (4.5%)     0.419      7 (3.0%)    12 (5.2%)     0.349
   Cardiac death                              39 (3.8%)               18 (3.2%)            21 (4.5%)     0.326      6 (2.6%)    12 (5.2%)     0.229
   Non-fatal MI                               40 (3.9%)               21 (3.8%)            19 (4.1%)     0.872      6 (2.6%)    11 (4.7%)     0.323
   Total revascularization                    13 (1.3%)               7 (1.3%)              6 (1.3%)     0.960      2 (0.9%)     2 (0.9%)     1.000
    TLR                                       13 (1.3%)               7 (1.3%)              6 (1.3%)     0.960      2 (0.9%)     2 (0.9%)     1.000
    TVR                                       13 (1.3%)               7 (1.3%)              6 (1.3%)     0.960      2 (0.9%)     2 (0.9%)     1.000
    Non-TVR                                   0 (0.0%)                0 (0.0%)              0 (0.0%)       \-       0 (0.0%)     0 (0.0%)       \-
   MACEs                                      54 (5.3%)               28 (5.1%)            26 (5.6%)     0.779     10 (4.3%)    14 (6.0%)     0.530
  Stent thrombosis (definite, probable)                                                                                                     
   Acute                                      7 (0.7%)                5 (0.9%)              2 (0.4%)     0.465      1 (0.4%)     0 (0.0%)     0.317
   Subacute                                   7 (0.7%)                3 (0.5%)              4 (0.9%)     0.708      1 (0.4%)     2 (0.9%)     0.562
   Total                                      14 (1.4%)               8 (1.4%)              6 (1.3%)     0.843      2 (0.9%)     2 (0.9%)     1.000
  1-yr follow-up                                                                                                                            
   All death                                  64 (6.3%)               38 (6.9%)            26 (5.6%)     0.440     14 (6.0%)    16 (6.9%)     0.851
    Cardiac death)                            52 (5.1%)               28 (5.2%)            24 (5.1%)     0.919     10 (4.3%)    15 (6.5%)     0.411
   Non-fatal MI                               55 (5.4%)               31 (5.6%)            24 (5.2%)     0.889      9 (3.9%)    12 (5.2%)     0.656
   Total revascularization                   100 (9.8%)              73 (13.2%)            27 (5.8%)    \< 0.001   25 (10.8%)   17 (7.3%)     0.257
    TLR                                       64 (6.3%)               49 (8.8%)            15 (3.2%)    \< 0.001   21 (9.1%)     8 (3.4%)     0.020
    TVR                                       73 (7.2%)              56 (10.1%)            17 (3.7%)    \< 0.001   22 (9.5%)     9 (3.9%)     0.024
    Non-TVR                                   10 (1.0%)               6 (1.1%)              4 (0.9%)     0.767      1 (0.4%)     3 (1.3%)     0.623
   MACEs                                     163 (16.0%)             110 (19.9%)           53 (11.5%)   \< 0.001   38 (16.4%)   33 (14.2%)    0.606
  Stent thrombosis (definite, probable)                                                                                                     
    Late (31--365 d)                          6 (0.6%)                6 (1.1%)              0 (0.0%)     0.035      2 (0.9%)     0 (0.0%)     0.156
    Total (1--365 d)                          20 (2.0%)               14 (2.5%)             6 (1.3%)     0.180      4 (1.7%)     2 (0.9%)     0.685
  3-yr follow-up                                                                                                                            
   All death                                  83 (8.2%)               53 (9.6%)            30 (6.5%)     0.085     21 (9.1%)    19 (8.2%)     0.869
   Cardiac death                              63 (6.2%)               37 (6.7%)            26 (5.6%)     0.516     12 (5.2%)    16 (6.9%)     0.559
   Non-fatal MI                               73 (7.2%)               42 (7.6%)            31 (6.7%)     0.627     14 (6.0%)    14 (6.0%)     1.000
   Total revascularization                   125 (12.3%)             85 (15.3%)            40 (8.7%)     0.001     30 (12.9%)   21 (9.1%)     0.235
    TLR                                       79 (7.8%)              58 (10.5%)            21 (4.5%)    \< 0.001   25 (10.8%)   10 (4.3%)     0.013
    TVR                                       93 (9.2%)              68 (12.3%)            25 (5.4%)    \< 0.001   27 (11.6%)   11 (4.7%)     0.010
    Non-TVR                                   14 (1.4%)               9 (1.6%)              5 (1.1%)     0.592      2 (0.9%)     3 (1.3%)     0.653
  MACEs                                      205 (20.2%)             134 (24.2%)           71 (15.4%)   \< 0.001   50 (21.6%)   41 (17.7%)    0.350
  Stent thrombosis (definite, probable)                                                                                                     
   Very late (366--1095 d)                    8 (0.8%)                6 (1.1%)              2 (0.4%)     0.303      2 (0.9%)     0 (0.0%)     0.156
   Total (1--1095 d)                          28 (2.8%)               20 (3.6%)             8 (1.7%)     0.083      6 (2.6%)     2 (0.9%)     0.285
  5-yr follow-up                                                                                                                            
   All death                                  90 (8.9%)              57 (10.3%)            33 (7.1%)     0.096     23 (9.9%)    21 (9.1%)     0.874
   Cardiac death                              67 (6.6%)               38 (6.9%)            29 (6.3%)     0.800     12 (5.2%)    18 (7.8%)     0.345
   Non-fatal MI                               91 (9.0%)               55 (9.9%)            36 (7.8%)     0.270     20 (8.6%)    16 (6.9%)     0.603
   Total revascularization                   148 (14.6%)             102 (18.4%)           46 (10.0%)   \< 0.001   39 (16.8%)   21 (9.1%)     0.018
    TLR                                       97 (9.5%)              74 (13.4%)            23 (5.0%)    \< 0.001   32 (13.8%)   10 (4.3%)     0.001
    TVR                                      112 (11.0%)             84 (15.2%)            28 (6.1%)    \< 0.001   35 (15.1%)   11 (4.7%)    \< 0.001
    Non-TVR                                   17 (1.7%)               10 (1.8%)             7 (1.5%)     0.809      3 (1.3%)     3 (1.3%)     1.000
   MACEs                                     236 (23.2%)             155 (28.0%)           81 (17.5%)   \< 0.001   61 (26.3%)   43 (18.8%)    0.058
  Stent thrombosis (definite, probable)                                                                                                     
   Very late (1096--1825 d)                   7 (0.7%)                6 (1.1%)              1 (0.2%)     0.134      1 (0.4%)     0 (0.0%)     0.317
   Very late (366--1825 d)                    15 (1.5%)               12 (2.2%)             3 (0.6%)     0.065      3 (1.3%)     0 (0.0%)     0.248
   Total (1--1825 d)                          35 (3.4%)               26 (4.7%)             9 (1.9%)     0.023      7 (3.0%)     2 (0.9%)     0.175

Values are presented as *n* (%). The *P* value for categorical data from chi-square test. DESs: drug-eluting stents; MI: myocardial infarction; MACE: major adverse cardiac events; TLR: target lesion revascularization; TVR: target vessel revascularization; 1G: first-generation; 2G: second-generation.

###### Five-year clinical outcomes by Kaplan-Meier curved analysis and cox-proportional hazard ratio model analysis.

  Outcomes                                 Cumulative Events at 5 years, %   Hazard Ratio (95% CI)   *P*-value                         
  --------------------------------------- --------------------------------- ----------------------- ----------- ---------------------- ----------
  Entire patients                                                                                                                      
  Primary outcomes                                                                                                                     
   All death                                         57 (10.3%)                    33 (7.1%)           0.089     1.447 (0.942--2.222)    0.091
   Cardiac death                                      38 (6.9%)                    29 (6.3%)           0.715     1.094 (0.675--1.774)    0.715
  Non-fatal myocardial infarction                    55 (10.2%)                    36 (8.1%)           0.317     1.239 (0.813--1.886)    0.319
   Total revascularization                           102 (19.6%)                  46 (10.8%)         \< 0.001    1.908 (1.347--2.703)   \< 0.001
   Target lesion revascularization                   74 (14.7%)                    23 (5.4%)         \< 0.001    2.744 (1.718--4.382)   \< 0.001
   Target vessel revascularization                   84 (16.5%)                    28 (6.8%)         \< 0.001    2.566 (1.673--3.937)   \< 0.001
  Non-target vessel revascularization                 10 (1.9%)                    7 (1.8%)            0.744     1.175 (0.447--3.090)    0.744
   MACEs                                             155 (28.0%)                  81 (18.1%)         \< 0.001    1.639 (1.253--2.145)   \< 0.001
  Secondary outcome                                                                                                                    
  Stent thrombosis                                    26 (4.7%)                    9 (1.9%)            0.018     2.432 (1.140--5.190)    0.022
  Propensity-matched patients                                                                                                          
   Primary outcomes                                                                                                                    
    All death                                         23 (9.9%)                    21 (9.1%)           0.783     1.087 (0.601--1.964)    0.783
    Cardiac death                                     12 (5.2%)                    18 (7.8%)           0.261     0.660 (0.318--1.370)    0.265
    Non-fatal myocardial infarction                   20 (8.9%)                    16 (7.3%)           0.608     1.187 (0.615--2.294)    0.609
    Total revascularization                          39 (17.8%)                    21 (9.7%)           0.021     1.874 (1.086--3.140)    0.023
    Target lesion revascularization                  32 (14.9%)                    10 (4.7%)           0.001     3.133 (1.539--6.376)    0.002
    Target vessel revascularization                  35 (16.2%)                    11 (5.2%)         \< 0.001    3.144 (1.596--6.192)    0.001
    Non-target vessel revascularization               3 (1.4%)                     3 (1.4%)            0.990     0.990 (0.200--4.906)    0.990
    MACEs                                            61 (26.3%)                   43 (18.8%)           0.077     1.419 (0.960--2.096)    0.079
  Secondary outcome                                                                                                                    
   Stent thrombosis                                   7 (3.0%)                     2 (0.9%)            0.094     3.524 (0.732--16.96)    0.116

Values are presented as *n* (%). DESs: drug-eluting stents; MACEs: major adverse cardiac events;1G: first-generation; 2G: second-generation.

![Kaplan-Meier curved analysis of MACEs-free survival (A, B), TLR (C, D), TVR (E, F) and stent thrombosis (G, H) at 5-year according to the generation of DES (1G *vs*. 2G) and types of DES (SES *vs*. PES *vs*. 1G-ZES *vs*. 2G-ZES *vs*. EES).\
DES: drug eluting balloon; EES: everolimus-eluting stent; MACEs: major adverse cardiac events; PES: paclitaxel-eluting stent; SES: sirolimus-eluting stent; TLR: target lesion revascularization; TVR: target vessel revascularization; ZES: zotarolimus-eluting stent; 1G: first-generation; 2G: second-generation.](jgc-15-08-523-g002){#jgc-15-08-523-g002}

![Subgroup analyses for MACE.\
ACC/AHA: American college of cardiology/American heart association; DESs: drug-eluting stents; LVEF: left ventricular ejection fraction; MACE: major adverse cardiac events; RAF: routine angiographic; STEMI: ST-segment elevation myocardial infarction; 1G: first-generation; 2G: second-generation.](jgc-15-08-523-g003){#jgc-15-08-523-g003}

4. Discussion {#s4}
=============

The main finding of this "real-world" PSM analysis was that the cumulative incidence of TLR, TVR and total revascularization rates were significantly higher in the 1G-DES group compared with 2G-DES group in AMI vessels after PSM analysis during 5-year follow-up periods. However, the incidence of total death, non-fatal MI and ST were similar between the two groups.

1G-DES (SES) could significantly reduce revascularization rates compared with BMS among patients with STEMI undergoing primary PCI.[@b9] However, 1G-DES can cause late ST due to delayed re-endothelization and poor strut coverage.[@b10] To overcome these limitations stent platforms and polymers have rapidly evolved during a short period. Newer antiproliferative drugs and more biocompatible polymers have been adapted in reducing the rate of late ST in stable coronary artery disease.[@b11]

4.1. Comparison with randomized controlled study {#s4a}
------------------------------------------------

Until recently, five randomized control trials (RCTs) comparing clinical outcomes of the 1G-DES versus 2G-DES in patients with AMI were conducted.[@b4],[@b12]--[@b15] However, their follow-up periods were less than 5 years (e.g., 7 months, 12 months, 18 months and 3 years). Among these 5 RCTs, 3 trials had compared ZES versus 1G-DES (two for ZES *vs*. SES *vs*. PES[@b4],[@b12]); one for ZES *vs*. SES[@b14]) and other 2 trials compared EES and SES.[@b13],[@b15] Four trials had evaluated only STEMI patients and one trial included 96% subjects with STEMI and 4% with non-ST segment elevation MI (NSTEMI)[@b13] and the number of included patients of these 5 RCTs ranged from 35 patients to 625 patients. Compared with these 5 RCTs, our study included relatively large number of NSTEMI patients (*n* = 482), and the total number of STEMI patients were up to 534. This means that our study might have included meaningful number of STEMI vessels. A meta-analysis report of above 5 RCTs[@b16] showed that 2G-DES could not showed a significant advantage over the 1G-DES in lowering the incidence of TLR, MACE, or all-cause death, only EES seemed to lower the occurrence of MACE than the 1G-DES. Although above 5 RCTs demonstrated useful clinical outcomes between 1G-DES and 2G-DES, more large scaled, randomized long-term follow-up studies are needed due to their relatively small study populations and short-term follow-up periods. In our study, 5-year cumulative incidence of MACE-free survival was significantly lower in the 1G-DES compared with 2G-DES in the entire patients (81.9% *vs*. 72.0%, Log-Rank: *P* \< 0.001, [Figure 2A](#jgc-15-08-523-g002){ref-type="fig"}). The main causes of this differences were caused by the difference between SES and 2G-ZES (Log-Rank: *P* = 0.007), SES and EES (Log-Rank: *P* = 0.001), PES and 2G-ZES (Log-Rank: *P* = 0.020), and PES and EES (Log-Rank: *P* = 0.002). Although the total cumulative incidence of MACE-free survival was not significantly different in PSM patients, EES\'s beneficial effect for MACE-free survival was sustained only between PES and EES (Log-Rank: *P* = 0.033, [Figure 2B](#jgc-15-08-523-g002){ref-type="fig"}).

4.2. Comparison with non-randomized controlled study {#s4b}
----------------------------------------------------

In non-randomized studies, Chen, *et al*.[@b3] analyzed 2911 AMI patients receiving PESs (*n* = 1210) or EESs (*n* = 1701). In his multicenter registry (Korea Acute Myocardial Infarction Registry, KAMIR) data, EESs group had significantly lower incidence of Re-MI (2.8% *vs*. 1.4%, *P* = 0.002), TLR (3.1% *vs*. 1.8%, *P* \< 0.001) and probable or definite ST (1.8% *vs*. 0.3%, *P* \< 0.001) than the PESs group during 1 year follow-up period. In our study, as shown in [Table 3](#jgc-15-08-523-t03){ref-type="table"}, [Figure 2C](#jgc-15-08-523-g002){ref-type="fig"} and [Figure 2D](#jgc-15-08-523-g002){ref-type="fig"}, the incidences of TLR were significantly higher in 1G-DES than 2G-DES after PSM (9.1% *vs*. 3.4%, *P* = 0.020) but Re-MI (3.9% *vs*. 5.2%, *P* = 0.656) and ST were 1.7% *vs*. 0.9%, *P* = 0.685) not significantly different during 1 year follow-up period. At 5 years, the cumulative incidence of TLR was significantly different between PES and EES (19.1% *vs*. 6.6%, Log-Rank: *P* = 0.013), PES and 2G-ZES (19.1% *vs*. 3.1%, Log-Rank: *P* = 0.001), SES and 2G-ZES (14.4% *vs*. 3.1%, Log-Rank: *P* = 0.014), and 1G-ZES and 2G-ZES (14.4% *vs*. 3.1%, *P* = 0.009). The 5-year cumulative incidence of TVR was significantly higher in 1G-DES than 2G-DES in entire patients (16.5% *vs*. 6.8%, Log-Rank: *P* \< 0.001, [Table 4](#jgc-15-08-523-t04){ref-type="table"}) and PSM patients (16.2% *vs*. 5.2%, Log-Rank: *P* = 0.001, [Table 4](#jgc-15-08-523-t04){ref-type="table"}, [Figures 2E](#jgc-15-08-523-g002){ref-type="fig"} and [2F](#jgc-15-08-523-g002){ref-type="fig"}). In this study, the comparison between the 2G-DESs (2G-ZES and EES) showed that 2G-ZES was non-inferior to EES in 5-year long-term clinical outcomes (MACE-free survival, ST, TLR, TVR, [Figures 2A](#jgc-15-08-523-g002){ref-type="fig"} to [2G](#jgc-15-08-523-g002){ref-type="fig"}) and as similar as previous studies.[@b6],[@b17]--[@b20] By contrast, there were several other different results on this comparison. Chen, *et al*.[@b21] also had reported another study comparing ZES and EES. They analyzed 3309 AMI patients treated with ZES (*n* = 1608) or EES (*n* = 1701) from KAMIR. After PSM analysis, EES significantly lowered the incidence of target lesion failure (TLF, 6.5% *vs*. 8.7%, *P* = 0.029) and probable or definite ST (0.3% *vs*. 1.6%, *P* \< 0.001) compared with ZES. We think one of important factors determine this different result is the difference in the follow-up period and Chen, *et al*. compared the EES with mainly with original ZES, not the 2G-ZES.

4.3. Comparison between 1G-ZES and 2G-ZES {#s4c}
-----------------------------------------

Characteristically ZES group divided separately as 1G-ZES and 2G-ZES and enrolled as 1G-DESs group or 2G-DESs group in this study. We think that even though endeavor^®^ or endeavor sprint^®^ (early-generation ZES) have relatively thinner stent strut and biocompatible polymer compared with SES or PES, in real-world practice they may be considered as 1G-DES and later-generation ZES (endeavor resolute^®^, resolute integrity^®^ and resolute onyx^®^) are really considered as 2G-DESs. There were also limited comparisons of long-term clinical outcomes in patients with AMI after PCI between 1G-ZES and 2G-ZES. The total MACE was not significantly different between these two stents (Log-Rank: *P* = 0.039 in entire patents, [Figure 2A](#jgc-15-08-523-g002){ref-type="fig"} and Log-Rank: *P* = 0.466 in PSM patients, [Figure 2B](#jgc-15-08-523-g002){ref-type="fig"}) during 5-year follow-up period in our study. However, in addition to increased TLR rate in 1G-ZES compared with 2G-ZES (as shown previously), TVR rate was also higher in 1G-ZES group compared with 2G-ZES (14.1% *vs*. 4.1%, Log-Rank: *P* = 0.009, [Figure 2F](#jgc-15-08-523-g002){ref-type="fig"}). However, the rate of stent thrombosis was not significantly different between the two groups (5.9% *vs*. 0.9%, Log-Rank: *P* = 0.054). Considering these several clinical outcomes, 1G-ZES showed similar clinical outcome patterns of other 1G-DESs (SES and PES).

4.4. Stent thrombosis {#s4d}
---------------------

Stent thrombosis is another debatable issue in the DES era. Several meta-analyses comparing SESs with PESs demonstrated no significant difference in ST between these two types of stents.[@b22],[@b23] But Schömig, *et al*.[@b24] showed that SESs was better than PESs in terms of reducing ST in his meta-analysis report. Previously mentioned 5 RCTs studies demonstrated that 2G-DES showed decreased incidence of definite or probable stent thrombosis compared with 1G-DES (RR: 0.53; 95% CI: 0.25--1.13; *P* = 0.10).[@b16] Hofma, *et al.*[@b7] reported the 3-year results of their all-comer, randomized, multicenter AMI trial (XAMI trial, Xience V stent *vs*. Cypher stent in Primary PCI for AMI trial). According to this report, the incidence of definite/probable ST was similar between the two groups (EES: 2.3% *vs*. SES: 3.2%, *P* = 0.60). In our study, the total and individual cumulative incidence of ST were not significantly different between 1G-DES and 2G-DES during 5-year follow-up periods in PSM patients ([Figure 2G](#jgc-15-08-523-g002){ref-type="fig"} and [Figure 2H](#jgc-15-08-523-g002){ref-type="fig"}). If the sample size were fully larger than our study, there may be statistically significant differences may be exist between 1G-ZES and 2G-ZES or EES.

4.5. Others {#s4e}
-----------

The RAF can increase revascularization due to possible 'oculo-stenotic reflex', a term describing revascularization with PCI according to anatomic lesion severity regardless of clinical or physiologic evidence of ischemia.[@b25] In our study, RAF was considered as an important bias and included covariate of PSM. After PSM this bias was abolished.

Until today, very long-term clinical follow-up data comparing 1G-DES *vs*. 2G-DES are rare and debatable especially in patients with AMI. The purpose of this study was to investigate the efficacy and safety of 2G-DES over 1G-DES regardless of specific types of DES in AMI patients during very long-term clinical follow-up periods. Most of the previous studies reported comparative results of only two-types or three-types of DESs, not considered each generation group as a whole.[@b3]--[@b5],[@b8],[@b11]--[@b15],[@b22]--[@b24] In addition to comparative analysis of 1G-DES *vs*. 2G-DES as a whole, we could obtain comparative subgroup results between different types of DESs through Kaplan-Meier curved analysis or Cox-regression analysis. During 5-year follow-up periods, we suggested 2G-DES\'s superiority for reducing TLR, TVR and total revascularization rates in AMI patients. However, this result maybe more precisely be defined by any other large and long-term follow-up randomized and controlled trials in the future. Under the circumstances where very long-term major clinical outcomes between 1G-DES and 2G-DES are still debatable, our results can be provide useful clinical outcome information and trends between 1G-DES and 2G-DES to some extent during very long-term follow-up periods in the DES era.

This study has some limitations. First, because it is a non-randomized registry design and single center study, several confounding factors such as under-reporting and/or missing value and selection bias may have affect the end results. Second, although PSM analysis and subgroup analysis done, the proportions of each stents in both groups were not evenly distributed. Third, in our study AMI patients were consisted of STEMI and NSTEMI. This heterogeneity can affect each other and may act as bias. Fourth, the strategy of antiplatelet therapy \[e.g., DAPT or triple antiplatelet therapy (TAPT)\] was left to the physician\'s discretion, which may have influenced the major clinical outcomes. Lastly, several important factors that can determine the end results such as total ischemia time could not be precisely obtained in our study patients.

In conclusion, in our single-center, all-comer registry, 2G-DES\'s superiority in reducing TLR, TVR and total revascularization rate over 1G-DES in AMI patients suggested during 5-year follow-up periods. Special cautions with careful clinical follow-up would be necessary for the AMI patients who are treating with 1G DESs in this aspect. However, long-term follow-up data from large scale, randomized studies are necessary to confirm these results.
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